NCT06829563 is a Phase 1 clinical trial of RZ-629 in Diabetes, sponsored by Rezubio Pharmaceuticals Co., Ltd..

Who is sponsoring NCT06829563?

NCT06829563 is sponsored by Rezubio Pharmaceuticals Co., Ltd..

What drugs are being tested in NCT06829563?

Interventions in NCT06829563: RZ-629, Placebo, Fasted, Fed.

Is NCT06829563 still recruiting?

NCT06829563 is currently recruiting now. Last updated 21 August 2025.

Last reviewed 2025-08-21 · How we verify

NCT06829563

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

Recruiting now Phase 1 Last updated 21 August 2025

What this trial tests

Phase 1 trial testing RZ-629 in Diabetes in 134 participants. Currently enrolling.

Timeline

30 January 2025

Primary endpoint
20 December 2025

20 February 2026

Quick facts

Lead sponsor	Rezubio Pharmaceuticals Co., Ltd.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	134
Start date	30 January 2025
Primary completion	20 December 2025
Estimated completion	20 February 2026
Sites	1 location across Australia

Drugs / interventions tested

RZ-629 — full drug profile →
Placebo
Fasted
Fed

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

Rezubio Pharmaceuticals Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy participants and T2D.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06829563 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rezubio Pharmaceuticals Co., Ltd.
Last refreshed: 21 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06829563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing